MetaCap

CorMedix (CRMD) vs Indaptus Therapeutics (INDP)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Indaptus Therapeutics (INDP) has outperformed CorMedix (CRMD) over the past year, gaining 52.4% versus a loss of 45.6%. Over five years, CRMD leads with a +3.9% price change compared with -98.3% for INDP. Indaptus Therapeutics is the larger company by market cap ($433.2 million vs $419.2 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CRMD-45.56%INDP+52.43%
+167%+52%-64%
Nov 21, 20251 yearNov 20, 2026
CRMD+2.73%INDP-98.22%
+204%+45%-114%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CRMD versus INDP key metrics
MetricCRMDINDP
Share price$5.27$2.82
Market cap$419.16M$433.16M
1-day change+3.74%-9.90%
YTD return-54.69%-3.09%
1-year return-45.56%+52.43%
5-year return+3.94%-98.26%
P/E ratio (TTM)8.23—
Forward P/E15.06—
EPS (TTM)$0.64$-3.16
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$311.71M—
Revenue growth (YoY)+617.03%—
Net income (latest FY)$163.06M$-20.85M
Gross margin88.46%—
Operating margin48.17%—
Net margin52.31%—
52-week high$13.02$5.96
52-week low$4.47$0.92
Distance from 52-week high-59.52%-52.68%
Analyst consensusbuy—
Avg. price target upside+161.86%—
Average volume1.44M712.87K
Shares outstanding79.54M153.60M
Employees1915
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • INDP has outperformed CRMD by 98.0 percentage points over the past year.

About CorMedix

CRMD stock →

CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure.

Health Care · Biotechnology: Pharmaceutical Preparations · 191 employees

About Indaptus Therapeutics

INDP stock →

Indaptus Therapeutics, Inc., a clinical biotechnology company, engages in the development of various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate consists of Decoy20, which is used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, as well as for the treatment of advanced solid tumors.

Health Care · Biotechnology: Pharmaceutical Preparations · 5 employees

CRMD vs INDP FAQ

Which is bigger, CorMedix or Indaptus Therapeutics?

Indaptus Therapeutics (INDP) is larger, with a market capitalization of $433.16M compared with $419.16M for CorMedix (CRMD).

Which stock has performed better over the past year, CRMD or INDP?

INDP returned +52.43% over the past 12 months, compared with -45.56% for CRMD (price return, excluding dividends). Past performance does not predict future results.

Are CorMedix and Indaptus Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons